Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2019, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.
Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 5, 1, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2019, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.
Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 5, 1, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Liver Failure (Hepatic Insufficiency) - Overview
Liver Failure (Hepatic Insufficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development
Celgene Corp
EA Pharma Co Ltd
Genentech Inc
Grifols SA
HepaRegeniX GmbH
Hepatx Corp
Immune Pharmaceuticals Inc
Mallinckrodt Plc
Martin Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
PledPharma AB
Promethera Biosciences SA
Proterris Inc
RHEACELL GmbH & Co KG
Steminent Biotherapeutics Inc
Takeda Pharmaceutical Co Ltd
Tianjin Weikai Bioeng Ltd
Unicyte AG
Liver Failure (Hepatic Insufficiency) - Drug Profiles
albumin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-3112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enasidenib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-573 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HepaStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipatasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTL-CEBPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resatorvid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
silibinin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Acute Liver Failure, Delayed Graft Function, Non-Alcoholic Steatohepatitis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Acute Liver Failure, Type 1 Diabetes and Urea Cycle Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Diabetic Foot Ulcers, Epidermolysis Bullosa, Liver Diseases, Kidney Disease, Peripheral Artery Occlusive Disease and Skin Ulcers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stemchymal - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trimetazidine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liver Failure (Hepatic Insufficiency) - Dormant Projects
Liver Failure (Hepatic Insufficiency) - Discontinued Products
Liver Failure (Hepatic Insufficiency) - Product Development Milestones
Featured News & Press Releases
Nov 11, 2019: Promethera Biosciences presents updated clinical results at AASLD 2019 for world’s first stem cell therapy trial using HepaStem in acute-on-chronic liver failure
May 09, 2019: Promethera Biosciences announces first-dosing in phase 2a clinical study evaluating world’s first liver stem cell therapy in late-stage NASH patients
Apr 15, 2019: Promethera Biosciences presents updated Phase 2a results for world’s first stem cell clinical trial in ACLF at The International Liver Congress/ EASL 2019
Mar 27, 2019: Promethera Biosciences announces late-breaking data presentation at EASL 2019 from World First Liver Stem Cell Clinical Trial in ACLF
Mar 12, 2019: Promethera Biosciences to attend and present at upcoming scientific and partnering conferences in March and April
Aug 29, 2018: cGMP Compliance Status for Promethera Biosciences’ Production Site in Durham, NC Confirmed by Health Canada
Mar 29, 2018: Martin Pharmaceuticals Receives FDA Orphan Drug Designation for LIVANTRA
Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016
Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure
Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases
Oct 05, 2015: Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Liver Failure (Hepatic Insufficiency) - Overview
Liver Failure (Hepatic Insufficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development
Celgene Corp
EA Pharma Co Ltd
Genentech Inc
Grifols SA
HepaRegeniX GmbH
Hepatx Corp
Immune Pharmaceuticals Inc
Mallinckrodt Plc
Martin Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
PledPharma AB
Promethera Biosciences SA
Proterris Inc
RHEACELL GmbH & Co KG
Steminent Biotherapeutics Inc
Takeda Pharmaceutical Co Ltd
Tianjin Weikai Bioeng Ltd
Unicyte AG
Liver Failure (Hepatic Insufficiency) - Drug Profiles
albumin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-3112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enasidenib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-573 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HepaStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipatasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTL-CEBPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resatorvid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
silibinin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Acute Liver Failure, Delayed Graft Function, Non-Alcoholic Steatohepatitis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Acute Liver Failure, Type 1 Diabetes and Urea Cycle Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Diabetic Foot Ulcers, Epidermolysis Bullosa, Liver Diseases, Kidney Disease, Peripheral Artery Occlusive Disease and Skin Ulcers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stemchymal - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trimetazidine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liver Failure (Hepatic Insufficiency) - Dormant Projects
Liver Failure (Hepatic Insufficiency) - Discontinued Products
Liver Failure (Hepatic Insufficiency) - Product Development Milestones
Featured News & Press Releases
Nov 11, 2019: Promethera Biosciences presents updated clinical results at AASLD 2019 for world’s first stem cell therapy trial using HepaStem in acute-on-chronic liver failure
May 09, 2019: Promethera Biosciences announces first-dosing in phase 2a clinical study evaluating world’s first liver stem cell therapy in late-stage NASH patients
Apr 15, 2019: Promethera Biosciences presents updated Phase 2a results for world’s first stem cell clinical trial in ACLF at The International Liver Congress/ EASL 2019
Mar 27, 2019: Promethera Biosciences announces late-breaking data presentation at EASL 2019 from World First Liver Stem Cell Clinical Trial in ACLF
Mar 12, 2019: Promethera Biosciences to attend and present at upcoming scientific and partnering conferences in March and April
Aug 29, 2018: cGMP Compliance Status for Promethera Biosciences’ Production Site in Durham, NC Confirmed by Health Canada
Mar 29, 2018: Martin Pharmaceuticals Receives FDA Orphan Drug Designation for LIVANTRA
Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016
Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure
Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases
Oct 05, 2015: Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Celgene Corp, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by EA Pharma Co Ltd, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Genentech Inc, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Grifols SA, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by HepaRegeniX GmbH, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Hepatx Corp, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Mallinckrodt Plc, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Martin Pharmaceuticals Inc, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Proterris Inc, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by RHEACELL GmbH & Co KG, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Steminent Biotherapeutics Inc, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Tianjin Weikai Bioeng Ltd, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H2 2019
Liver Failure (Hepatic Insufficiency) - Dormant Projects, H2 2019
Liver Failure (Hepatic Insufficiency) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Liver Failure (Hepatic Insufficiency) - Discontinued Products, H2 2019
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Celgene Corp, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by EA Pharma Co Ltd, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Genentech Inc, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Grifols SA, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by HepaRegeniX GmbH, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Hepatx Corp, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Mallinckrodt Plc, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Martin Pharmaceuticals Inc, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Proterris Inc, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by RHEACELL GmbH & Co KG, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Steminent Biotherapeutics Inc, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Tianjin Weikai Bioeng Ltd, H2 2019
Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H2 2019
Liver Failure (Hepatic Insufficiency) - Dormant Projects, H2 2019
Liver Failure (Hepatic Insufficiency) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Liver Failure (Hepatic Insufficiency) - Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Celgene Corp
EA Pharma Co Ltd
Genentech Inc
Grifols SA
HepaRegeniX GmbH
Hepatx Corp
Immune Pharmaceuticals Inc
Mallinckrodt Plc
Martin Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
PledPharma AB
Promethera Biosciences SA
Proterris Inc
RHEACELL GmbH & Co KG
Steminent Biotherapeutics Inc
Takeda Pharmaceutical Co Ltd
Tianjin Weikai Bioeng Ltd
Unicyte AG
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Celgene Corp
EA Pharma Co Ltd
Genentech Inc
Grifols SA
HepaRegeniX GmbH
Hepatx Corp
Immune Pharmaceuticals Inc
Mallinckrodt Plc
Martin Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
PledPharma AB
Promethera Biosciences SA
Proterris Inc
RHEACELL GmbH & Co KG
Steminent Biotherapeutics Inc
Takeda Pharmaceutical Co Ltd
Tianjin Weikai Bioeng Ltd
Unicyte AG
